Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) has earned a consensus recommendation of “Hold” from the fifteen analysts that are currently covering the firm, Marketbeat reports. Two equities ...

In terms of liquidity and interest, the mean open interest for Hims & Hers Health options trades today is 1566.44 with a ...

What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an ...

Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Hims & Hers Health stock corrected after earnings because of the outlook on its key GLP-1 medication. See why I rate HIMS a ...

We recently published a list of Why These 15 Defensive Stocks Are Surging In 2025. In this article, we are going to take a ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering ...